| 0 (0%) | 11-11 19:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.33 | 1-year : | 34.26 |
| Resists | First : | 25.11 | Second : | 29.33 |
| Pivot price | 24.94  |
|||
| Supports | First : | 24.46 | Second : | 24.06 |
| MAs | MA(5) : | 25.04 |
MA(20) : | 24.8 |
| MA(100) : | 24.13 |
MA(250) : | 24.78  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.3 |
D(3) : | 87.7 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 27.34 | Low : | 22.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QLS ] has closed below upper band by 21.5%. Bollinger Bands are 64% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 25.1 - 25.22 | 25.22 - 25.35 |
| Low: | 24.59 - 24.72 | 24.72 - 24.86 |
| Close: | 24.88 - 25.08 | 25.08 - 25.29 |
Mon, 10 Nov 2025
Contributions to profession recognised - qlsproctor.com.au
Fri, 19 Sep 2025
Swedish Quantum Life Science - Karolinska Institutet
Tue, 26 Aug 2025
Qlaris Bio Announces First Patient Dosed in Phase II Nightingale Clinical Trial in Normal Tension Glaucoma Patients - Business Wire
Tue, 26 Aug 2025
First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111 - Optometry Times
Thu, 12 Jun 2025
Qlaris Bio announces development of QLS-111-FDC - Ophthalmology Times
Wed, 11 Jun 2025
Qlaris Bio developing fixed-dose latanoprost and QLS-111 eye drop for glaucoma - Eyes On Eyecare
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|